Shigeki Yoshiura
5PUBLICATIONS
12CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (5)
Sort by Publication Date:
|Oct 27, 2025
Polatuzumab Vedotin Induced CD20 Upregulation Contributes to the Efficacy of Mosunetuzumab in Combination With Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma Preclinical Models.Natsumi Kawasaki, Sei Shu, Mayu Tomita
|Nov 17, 2024
Targeting ErbB and tankyrase1/2 prevent the emergence of drug-tolerant persister cells in ALK-positive lung cancer.Takaaki Fujimura, Koh Furugaki, Hayato Mizuta
|Oct 06, 2024
Combined blockade of GPX4 and activated EGFR/HER3 bypass pathways inhibits the development of ALK-inhibitor-induced tolerant persister cells in ALK-fusion-positive lung cancer.Koh Furugaki, Takaaki Fujimura, Narumi Sakaguchi
|Oct 25, 2023
FGFR blockade inhibits targeted therapy-tolerant persister in basal FGFR1- and FGF2-high cancers with driver oncogenes.Koh Furugaki, Takaaki Fujimura, Hayato Mizuta
|Aug 07, 2023
Efficacy of retreatment with polatuzumab vedotin in combination with rituximab in polatuzumab vedotin-resistant DLBCL models.Natsumi Kawasaki, Mayu Tomita, Yoriko Yamashita-Kashima
Pageof 1
Frequent Collaborators
3 joint publications
Koh Furugaki
2 joint publications
Natsumi Kawasaki
2 joint publications
Mayu Tomita
2 joint publications
Yoriko Yamashita-Kashima
2 joint publications
Ryohei Katayama
1 joint publications
Takuya Yoshimoto
1 joint publications
Hayato Mizuta
1 joint publications
Jun Adachi
1 joint publications
Ken Uchibori
1 joint publications
Eisaku Miyauchi
